A rare case of H3K27-altered diffuse midline glioma with multiple osseous and spinal metastases at the time of diagnosis.
Diffuse midline Glioma
Extraneural metastases
H3K27M
Neuro-oncology
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
28 Feb 2023
28 Feb 2023
Historique:
received:
24
10
2022
accepted:
21
02
2023
entrez:
1
3
2023
pubmed:
2
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
H3K27-altered diffuse midline gliomas are uncommon central nervous system tumors with extremely poor prognoses. We report the case of a 24-year-old man patient with multiple, inter alia osseous metastases who presented with back pain, hemi-hypoesthesia, and hemi-hyperhidrosis. The patient underwent combined radio-chemotherapy and demonstrated temporary improvement before deteriorating. H3K27-altered diffuse midline glioma presents an infrequent but crucial differential diagnosis and should be considered in cases with rapid neurological deterioration and multiple intracranial and intramedullary tumor lesions in children and young adults. Combined radio-chemotherapy delayed the neurological deterioration, but unfortunately, progression occurred three months after the diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
H3K27-altered diffuse midline gliomas are uncommon central nervous system tumors with extremely poor prognoses.
CASE PRESENTATION
METHODS
We report the case of a 24-year-old man patient with multiple, inter alia osseous metastases who presented with back pain, hemi-hypoesthesia, and hemi-hyperhidrosis. The patient underwent combined radio-chemotherapy and demonstrated temporary improvement before deteriorating.
CONCLUSIONS
CONCLUSIONS
H3K27-altered diffuse midline glioma presents an infrequent but crucial differential diagnosis and should be considered in cases with rapid neurological deterioration and multiple intracranial and intramedullary tumor lesions in children and young adults. Combined radio-chemotherapy delayed the neurological deterioration, but unfortunately, progression occurred three months after the diagnosis.
Identifiants
pubmed: 36855102
doi: 10.1186/s12883-023-03135-4
pii: 10.1186/s12883-023-03135-4
pmc: PMC9972747
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Informations de copyright
© 2023. The Author(s).
Références
Neurooncol Adv. 2020 Nov 18;3(1):vdaa156
pubmed: 33543143
Front Oncol. 2021 Dec 08;11:701113
pubmed: 34956856
Neuro Oncol. 2016 Feb;18(2):298-300
pubmed: 26803811
J Neurooncol. 2019 May;143(1):87-93
pubmed: 30864101
Neurosurgery. 1991 Feb;28(2):302-6
pubmed: 1847741
Surg Neurol. 2005 Jun;63(6):511-9; discussion 519
pubmed: 15936366
Case Rep Oncol. 2018 Aug 28;11(2):591-600
pubmed: 30283316
Neurology. 2019 Aug 13;93(7):e729-e730
pubmed: 31405944
Neurooncol Pract. 2020 Aug 29;8(1):4-10
pubmed: 33664964
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
Mol Clin Oncol. 2016 Oct;5(4):437-439
pubmed: 27699039
Neurosurgery. 2005 May;56(5):972-81; discussion 972-81
pubmed: 15854245
J Korean Neurosurg Soc. 2012 Mar;51(3):147-50
pubmed: 22639711
Acta Neuropathol. 2019 Feb;137(2):297-306
pubmed: 30460397
Oncol Lett. 2013 Mar;5(3):992-996
pubmed: 23426283
J Neurooncol. 2012 Mar;107(1):21-7
pubmed: 21964740
Medicine (Baltimore). 2017 Apr;96(16):e6634
pubmed: 28422860
Neurol Neurochir Pol. 2009 Mar-Apr;43(2):183-90
pubmed: 19484696
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Case Rep Oncol Med. 2017;2017:2938319
pubmed: 29201475
J Clin Oncol. 2014 Aug 1;32(22):e80-4
pubmed: 24567434
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Clin Cancer Res. 2018 Jun 15;24(12):2812-2819
pubmed: 29615461